Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22042695 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL3390943 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL3033547 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL6159262 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL920271 | 0.97 | — | — | |
| SCHEMBL1524591 | 0.91 | TSHR (0.41) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL6163254 | 0.91 | TSHR (0.41) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL1534018 | 0.91 | TSHR (0.41) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL6159886 | 0.91 | TSHR (0.41) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL9213664 | 0.91 | TSHR (0.41) | TSHRTHRBFAAHTRPV1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013385-B1 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2024-07-03 | — | — | EP | disclosed |
| US-20240158458-A1 | MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNA TX INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-11969506-B2 | Lipid nanoparticle formulation | MODERNATX, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240124388-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-18 | — | — | US | disclosed |
| US-20240024422-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-3458105-B1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | MODERNATX INC (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117224710-A | Immunomodulatory therapeutic MRNA compositions encoding mutant peptides that activate oncogenes | 莫得纳特斯公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4286012-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230346928-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ARES CAPITAL CORPORATION, AS AGENT | 2023-11-02 | — | — | US | disclosed |
| US-20230330260-A1 | RNA FORMULATIONS | ModemaTX, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-17 | — | — | US | disclosed |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-10 | — | — | US | disclosed |
| WO-2017127750-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | disclosed |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | disclosed |
| WO-2017106799-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-0893442-B1 | LYMPH-ABSORBABLE IMIDAZOLE DERIVATIVES | SHIONOGI & CO (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6054591-A | LYMPHOTROPIC ANTI-AIDS AGENT | SHIONOGI & CO., LTD. (JP) | 2000-04-25 | — | — | US | disclosed |
| EP-0893442-A1 | LYMPH-ABSORBABLE IMIDAZOLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1999-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | TSHR 3089/4885THRB 3096/4885FAAH 3137/4885 |
| US-11969506-B2 | Lipid nanoparticle formulation | TTPA, SREBF1, SREBF2 | TSHR 1913/4885THRB 1782/4885FAAH 2258/4885 |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | TSHR 3089/4885THRB 3096/4885FAAH 3137/4885 |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | TSHR 3089/4885THRB 3096/4885FAAH 3137/4885 |
| US-20230330260-A1 | RNA FORMULATIONS | SYNCRIP, NSUN3, RNMT | TSHR 3530/4885THRB 4303/4885FAAH 1603/4885 |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | TSHR 3089/4885THRB 3096/4885FAAH 3137/4885 |
| US-20230346928-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | CD274, PDCD1LG2, ICOSLG | TSHR 1875/4885THRB 4242/4885FAAH 4829/4885 |
| US-20240024422-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | IL2, IL15, RBM12 | TSHR 3940/4885THRB 4329/4885FAAH 4084/4885 |
| US-20240124388-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | TSHR 3089/4885THRB 3096/4885FAAH 3137/4885 |
| US-20240158458-A1 | MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | IL2, LCP2, IFNG | TSHR 1274/4885THRB 2469/4885FAAH 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.